C12N 2770/12011
Astroviridae
C12N2770/12011 (Astroviridae) appears on 32 US grants and 45 published applications in this corpus.
Search patents in C12N- Granted patents
- 32
- Published applications
- 45
- Assignees
- 25
- Inventors
- 67
- Latest grant
- 13 May 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 2 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 3 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 2 |
| 2011 | 1 | 7 |
| 2012 | 4 | 1 |
| 2013 | 2 | 2 |
| 2014 | 3 | 1 |
| 2015 | 2 | 5 |
| 2016 | 2 | 2 |
| 2017 | 1 | 1 |
| 2018 | 3 | 1 |
| 2019 | 2 | 3 |
| 2020 | 1 | 1 |
| 2021 | 2 | 3 |
| 2022 | 0 | 2 |
| 2023 | 1 | 2 |
| 2024 | 0 | 4 |
| 2025 | 1 | 1 |
| 2026 | 0 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/12022New viral proteins or individual genes, new structural or functional aspects ofIndexing code20
- C12N 2770/12033Use of viral protein as therapeutic agent other than vaccineIndexing code11
- C12N 2770/12051Methods of production or purification of viral materialIndexing code7
- C12N 2770/12034Use of virus or viral component as vaccineIndexing code6
- C12N 2770/12021Viruses as suchIndexing code5
- C12N 2770/12071Demonstrated in vivo effectIndexing code5
- C12N 2770/12061Methods of inactivation or attenuationIndexing code2
- C12N 2770/12023Virus like particles [vlp]Indexing code1
All 12 subgroupsShow fewer
Recent patents
- Synthetic peptide compounds and methods of use13 May 2025US 12,297,235 B2Realta Holdings, LLC
- Synthetic peptide compounds and methods of use14 Nov 2023US 11,814,414 B2Realta Holdings, LLC
- Synthetic peptide compounds and methods of use16 Mar 2021US 10,947,279 B2Realta Holdings, LLC
- Synthetic peptide compounds and methods of use2 Mar 2021US 10,933,116 B2Realta Holdings, LLC
- Peptide compounds to regulate the complement system24 Nov 2020US 10,844,093 B2Realta Holdings, LLC
- Peptide compounds to regulate the complement system24 Sep 2026US 2026/0285907 A1Realta Holdings, LLC
- Synthetic peptide compounds and methods of use14 May 2026US 2026/0132170 A1Realta Holdings, LLC
- Peptide compounds to regulate the complement system29 Jan 2026US 2026/0028373 A1Realta Holdings, LLC
- Peptide compounds to regulate the complement system24 Apr 2025US 2025/0129124 A1Realtaholdings,LLC
- Anti-Human Astrovirus Antibodies and Related Compositions and Methods28 Nov 2024US 2024/0391980 A1The Regents of the University of California
Most cited
By later US patents
- Antisense antiviral compound and method for treating ssRNA viral infection37US 8,906,872 B2Sarepta Therapeutics, Inc. · 2014
- Antisense antiviral compound and method for treating ssRNA viral infection32US 8,084,433 B2AVI BioPharma, Inc. · 2011
- Antisense antiviral compound and method for treating ssRNA viral infection32US 8,129,352 B2AVI BioPharma, Inc. · 2012
- Avian astrovirus19US 6,696,562 B1The United States of America as represented by the Secretary of Agriculture · 2004
- Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof14US 8,241,843 B2Eastern Virginia Medical School · 2012